Clinical Trial
Share your love
Regeneron’s High-Dose Aflibercept Receives FDA Approval
Regeneron has received FDA approval for Eylea HD (aflibercept 8 mg) in a significant development anticipated to substantially extend dosing intervals for patients with retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).…
FDA Rejects Lytenava by Outlook Therapeutics for Wet AMD
Outlook Therapeutics announced that the FDA has issued a complete response letter (CRL) regarding the company’s Biologics License Application (BLA) for ONS-5010 (Lytenava). ONS-5010 is an investigative ophthalmic formulation of bevacizumab aimed at treating wet AMD. While the FDA recognized…
LumiThera Receives $2.3M NIH Grant for Dry AMD Trial
LumiThera has been granted a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH), totaling up to $2.3 million in funding over a span of 2 years. This NIH/NEI grant is geared towards supporting…
Iveric Bio’s Izervay for Geographic Atrophy Approved by FDA
Parent company Astellas Pharma announced that Iveric Bio has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a new complement C5 inhibitor, Izervay stands out as the sole…
Best Treatment for Uveitic Macular Edema Identified
Repeat corticosteroid injections were found to be more effective in improving vision for individuals with persistent or recurrent uveitis-related macular edema compared to methotrexate or ranibizumab intravitreal injections, according to a recent clinical trial. The corticosteroid treatment exhibited superior results…
Naegis Pharma Funds Novel Eye Drug
Naegis Pharmaceuticals Inc., a life sciences company specializing in inflammation and ophthalmology, announced the successful closure of a financing round to advance its lead compound, N0651, towards a Phase 2 clinical trial. This funding will support the compound’s progression through…
Glaucomatous Optic Neuropathy & Latest Treatments
Glaucomatous optic neuropathy is characterized by progressive loss of retinal ganglion cells (RGCs) and their axons and leads to measureable structural and functional damage to the optic nerve, visual impairment, and blindness. The primary site of injury is thought to be…
SpyGlass Pharma Secures $90M in Funding
SpyGlass Pharma has successfully closed a Series C financing round, raising $90 million. RA Capital Management led the funding round, joined by existing investors New Enterprise Associates (NEA) and Vensana Capital, as well as new investors Samsara BioCapital and Vertex…
Ocugen Completes Dosing in Key Trial for GA Treatment
Ocugen has officially completed dosing in the second cohort of its phase 1/2 ArMaDa trial of OCU410, a novel gene therapy designed to treat geographic atrophy (GA). The therapy, known as adeno-associated viral vector 5 human RORA (AAV5-hRORA), is being…
A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease: results from a randomized, placebo-controlled clinical trial – Frontiers
A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease: results from a randomized, placebo-controlled clinical trial Frontiers Source: Author: | Date: 2024-04-23 07:00:00 Source: Author: | Date: 2024-04-23 07:00:00